Recro Pharma's loss under GAAP for 9 months of 2020 was $15.831 million, up 73.6% from $9.119 million the previous year. Revenue decreased by 30.6% to $56.586 million, against $81.576 million a year earlier.
Recro Pharma's loss under GAAP for 9 months of 2020 was $15.831 million, up 73.6% from $9.119 million the previous year. Revenue decreased by 30.6% to $56.586 million, against $81.576 million a year earlier. 
ir.recropharma.com
English (US) 